TY -的T1 -更大的非典型抑郁症状的发生率帕金森症:早期筛查的重要性(S19.005) JF -神经学乔-神经学六世- 86 - 16补充SP - S19.005盟艾哈迈德-莱昂纳多阿尔梅达盟盟-罗杰Walz AU - Sol De耶稣盟艾迪帕特森A首页U -丹尼尔Martinez-Ramirez AU -大卫·瓦兰蔻盟黎明Bowers AU -赫伯特·沃德AU -迈克尔·奥肯盟梅丽莎·阿姆斯特朗AU -尼古拉斯麦克法兰Y1 - 2016/04/05 UR - //www.ez-admanager.com/content/86/16_Supplement/S19.005.abstract N2 -背景:尽管相对较少和较小规模的研究解决抑郁症状的发生在非典型帕金森(adp)患者中,抑郁似乎更频繁的比在帕金森病(PD)患者。本研究旨在评估帕金森患者的抑郁症状的发生率。方法:我们确定了美国患者的回顾性队列(MSA, PSP, CBD,和下文)和年龄性别匹配的PD控制,参与了UF-INFORM数据库从2007 - 2015。抑郁症状在初始和后续遇到评估采用贝克抑郁量表(BDI)。受试者没有抑郁症(BDI≤13)在初始遇到纵向随访和评估抑郁症状。发病率和确定kaplan - meier估计累积抑郁症状的发生率在不同组。结果:我们发现69年CBS, 60下文,130 MSA, 102 PSP, 2352 PD科目没有抑郁症状在最初的相遇。在这一群人,事件率的抑郁症状(BDI祝辞13)是13.7每100人每年为PD和16.6 adp子组(MSA: 21.9,哥伦比亚广播公司(CBS): 27.1,下文:26.5,PSP: 52.8)。1 -生存曲线显示统计学意义(& lt; 0.001)之间的差异不同的子组,和多个物流Cox回归显示风险之间的比率明显高于下文(HR 4.08,可信区间1.19 - -13.98,p = 0.02)和PSP (HR 3.32, CI 95 (percnt) 1.28 - 8.56, p = 0.01)相比,PD。结论:在基线帕金森病人没有抑郁症,有一个后续的抑郁症发病率特别高PSP和下文的病人比那些PD。 These findings emphasize the importance of longitudinal screening for depression in parkinsonian patients even when there are no mood concerns at baseline, particularly as studies in parkinsonism frequently link depression and QoLDisclosure: Dr. Almeida has nothing to disclose. Dr. Ahmed has nothing to disclose. Dr. Walz has nothing to disclose. Dr. De Jesus has nothing to disclose. Dr. Patterson has nothing to disclose. Dr. Martinez-Ramirez has nothing to disclose. Dr. Vaillancourt has received research support from NIH, Michael J. Fox Foundation, Bachmann-Strauss Foundation, Tyler's Hope Foundation, and UT Southwestern Medical Center. Dr. Bowers has nothing to disclose. Dr. Ward has nothing to disclose. Dr. Okun has received royalty payments from Demos, Humana, Amazon, Smashwords, Books4Patients, and Cambridge. Dr. Okun has received research support from the Michael J. Fox Foundation, the National Parkinson Foundation, the Parkinson Alliance, the Smallwo Dr. Armstrong has received personal compensation from the American Academy of Neurology as a consultant. Dr. Armstrong has received research support from Abbvie, the Parkinson Study Group (PSG), the Huntington Study Group (HSG), and CHDI Foundation, Inc. Dr. McFarland has nothing to disclose.Monday, April 18 2016, 6:30 am-8:30 am ER -